tradingkey.logo

Lirum Therapeutics Ord Shs (Proposed)

LRTX
0.000
Close 12/24, 13:00ETQuotes delayed by 15 min
--Market Cap
--P/E TTM
You can access the annual and quarterly cash flow statements of Lirum Therapeutics Ord Shs (Proposed) to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2024Q1
FY2023Q4
FY2023Q1
FY2022Q4
Operating cash flows (indirect method)
Cash flow from continuing operating activities
---743.36K
21.65%-212.82K
---616.13K
---271.62K
Net income from continuing operations
---739.34K
83.80%-298.20K
---589.76K
---1.84M
Change in working capital
---4.02K
-94.56%85.38K
---26.37K
--1.57M
Cash from non-recurring investing activities
Cash from operating activities
---743.36K
21.65%-212.82K
---616.13K
---271.62K
Investing cash flow
Cash from non-current investing activities
Financing cash flow
Cash flow from continuous financing activities
--0.00
-100.00%0.00
--6.08M
--380.00K
Net cash flow from debt Issuance/repayment
--0.00
-100.00%0.00
--250.00K
--400.00K
Net cash flow from common stock issuance/repurchase
--0.00
--0.00
--5.84M
--0.00
Net cash flow from other financing activities
--0.00
100.00%0.00
---10.00K
---20.00K
Net cash from non-recurrent financing activities
Net cash from financing activities
--0.00
-100.00%0.00
--6.08M
--380.00K
Net cash flow
Beginning cash balance
--4.01M
6293.50%4.22M
--174.41K
--66.03K
Current period cash flow changes
---743.36K
-296.37%-212.82K
--5.46M
--108.38K
Ending cash balance
--3.27M
2198.57%4.01M
--5.63M
--174.41K
Currency unit
USD
USD
USD
USD
Audit opinions
--
--
--
--

FAQs

What is the cash flow statement?

This report tracks the movement of cash into and out of the business, covering operating, investing, and financing activities. It highlights how well the company manages cash to support growth and meet its obligations.
KeyAI